N/A
Completed N=7,740
DELIVER Study: DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER Stenting
Source: ClinicalTrials.gov NCT01297257 ↗Enrolled (actual)
7,740
Serious AEs
1.6%
Results posted
Mar 2014
Primary outcomePrimary: Delivery Success — 10617 stents
Summary
The primary objective of the DELIVER Study is to assess the deliverability of the Resolute Integrity Stent as primary stent or as a secondary cross-over stent following delivery failure of another stent type in real world patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Delivery Success |
10617 | — |
| SECONDARY In-hospital MACE (Major Adverse Cardiac Event) |
126 | — |
Eligibility Criteria
Inclusion Criteria
- Minimum legal age (18)
- Acceptable candidate for treatment with a drug-eluting stent in accordance with applicable guidelines
- Patient has consented to participate and authorized in writing the collection and release of medical information
Exclusion Criteria
- Pregnancy
- Participating in another study that interferes with study endpoints
- Untreatable hypersensitivity or allergies to aspirin, heparin, clopidogrel, zotarolimus or similar drugs or contrast media
- Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated
Data sourced from ClinicalTrials.gov (NCT01297257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.